<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710734</url>
  </required_header>
  <id_info>
    <org_study_id>GU-086</org_study_id>
    <secondary_id>15-1071</secondary_id>
    <nct_id>NCT02710734</nct_id>
  </id_info>
  <brief_title>Risk Adapted Treatment for Muscle Invasive Bladder Cancer After Neoadjuvant Accelerated MVAC</brief_title>
  <official_title>A Phase II Trial of Risk Adapted Treatment for Muscle Invasive Bladder Cancer After Neoadjuvant Accelerated MVAC (RAT-MIBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle
      invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT)
      sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate,
      vinblastine, doxorubicin, and cisplatin (AMVAC) chemotherapy. Based on the mutational profile
      and the post AMVAC TURBT findings, patients will be treated with active surveillance
      (experimental arm), or standard of care intravesicle therapy, chemoradiation or surgery. We
      hypothesize that this approach will lead to non-inferior metastasis-free survival at 2 years,
      while preserving the bladder and thus quality-of-life for a proportion of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2016</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-free survival (MFS) at 2 years.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to complete of 3 cycles of neoadjuvant AMVAC and chemoradiation therapy with 5-FU and mitomycin C.</measure>
    <time_frame>Up to 37 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of urothelial carcinoma recurrence in active surveillance patients</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival and PFS of the entire cohort</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>toxicity during each treatment arm according to NCI CTCAE v 4.01 criteria</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with ≥cT1 disease after TURBT#2</measure>
    <time_frame>up to 22 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients requiring a cystectomy, either immediately after TURBT#2 or as salvage after surveillance or CRT</measure>
    <time_frame>up to 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Endoscopic Tumor Quantification System score at each TURBT</measure>
    <time_frame>24 months</time_frame>
    <description>At each cystoscopic examination, the location and extent of tumor volume will be visually depicted and graded according to Endoscopic Tumor Quantification System</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life with neoadjuvant AMVAC and subsequent risk-adapted treatment</measure>
    <time_frame>60 months</time_frame>
    <description>American Urologic Association (AUA) Symptom Index Score, Sexual Health Inventory for Men (SHIM) score or Female Sexual Function Index (FSFI) score</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Urothelial Carcinoma of the Bladder</condition>
  <arm_group>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered Day 1 of each 14 day cycle for 3 cycles</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiation therapy (IMRT)</intervention_name>
    <description>2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday</description>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transurethral Resection of Bladder tumor</intervention_name>
    <description>Performed at before and after AMVAC and after chemoradiation and intravesicle therapy</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>Surveillance</arm_group_label>
    <arm_group_label>Intravesicle therapy</arm_group_label>
    <arm_group_label>Radical Cystectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment</description>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Intravenous on day 1 with radiation treatment</description>
    <arm_group_label>CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥18 years.

          -  Primary urothelial or predominantly urothelial carcinoma of the bladder.

          -  Histologic evidence of muscularis propria invasion.

          -  AJCC27 clinical stage T2-T4a .

          -  No radiographic evidence of lymph node positivity (N0) or metastatic disease (M0).
             Clinical lymphadenopathy on staging CT greater than 1.5 cm in short axis must be
             biopsy proven negative.

          -  ECOG performance status 0, 1, or 2.

          -  Left ventricular ejection fraction ≥ 50% by MUGA or ECHO within 6 months of study
             entry.

          -  Normal organ and bone marrow function as defined:

        Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total
        bilirubin ≤ institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 2.5 X
        institutional ULN Creatinine Creatinine Clearance ≥ 50 mL/min (calculated using the
        Cockroft-Gault formula or measured with 24 hour urine collection)

        Exclusion Criteria:

          -  Any component of small cell histology.

          -  Prior pelvic radiation therapy or patients who have undergone prior radiation to
             greater than or equal to 25% of the bone marrow within the past year are excluded due
             to risk of life threatening myelosuppression

          -  Prior systemic chemotherapy; patients who have received any previous systemic
             chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy
             for another malignancy within 1 year of study entry are ineligible.

          -  Prior or concurrent malignancy of any other site except for non-melanoma skin cancer,
             unless disease free interval ≥ 5 years.

          -  Patients who have received experimental agents within 4 weeks of study entry.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Methotrexate, Vinblastine, Adriamycin or Cisplatin or other agents used
             in the study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection (defined by current oral or intravenous antibiotic therapy), symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Pregnant women are excluded from this study due to the potential for teratogenic or
             abortifacient effects of cytotoxic chemotherapy.

          -  Known HIV-positive patients on combination antiretroviral therapy are ineligible
             because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy.
             In addition, these patients are at increased risk of lethal infections when treated
             with marrow-suppressive therapy.

          -  Patients with hydronephrosis that has not been addressed with an intervention such as
             placement of a stent.

          -  Pregnancy &amp; Women of Childbearing Potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Geynisman, MD</last_name>
    <phone>215-214-1515</phone>
    <email>Daniel.Geynisman@fccc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Geynisman, MD</last_name>
      <phone>215-728-4300</phone>
      <email>daniel.geynisman@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Geynisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

